

# CUMULATIVE INDEX 1995

## Volume 11

January	RESPIRATORY PROCEDURES AND MONITORING, pages 1-253
April	GASTROINTESTINAL EMERGENCIES, pages 255-567
July	NUTRITION IN THE CRITICALLY ILL PATIENT, pages 569-790
October	SEDATION OF THE CRITICALLY ILL PATIENT, pages 791-1039

Note: Page numbers of article titles are in **boldface** type

- Abdomen, pain of, in AIDS, 532-533  
as source of sepsis, **255-272**. See also *Sepsis, abdominal*.
- Abscess(es), in Crohn's disease, 522-523  
diverticular, 262  
pancreatic, 318
- Absorbance-based optical sensor, diagram of, 242
- Absorptiometry, dual-energy x-ray, in nutritional assessment, 617-619
- Acquired immunodeficiency syndrome (AIDS), abdominal pain in, 532-533  
acute acalculous cholecystitis in, 277-278  
*Clostridium difficile* and, 541-542  
esophageal disease in, 533-534  
gastrointestinal emergencies in, **531-560**  
causes, 534-544  
CMV colitis, 535-539  
gastrointestinal bleeding, 546-548  
intractable diarrhea, 548-553  
Kaposi's sarcoma, 542-544  
mycobacterium tuberculosis, 540-541  
hepatobiliary tract disorders in, 544-546
- Acute renal failure (ARF), amino acid loss in, 693  
carbohydrate metabolism in, 689  
categories, 685  
described, 685  
electrolytes in, 689  
energy expenditure in, 686-689  
glucose loss in, 693  
growth factors in, 700  
lipid metabolism in, 689  
malnutrition, causes, 688  
metabolic changes in, 686-694  
nutrient requirements in, 689-690  
nutritional support in, **685-704**  
catabolism assessment, 695-696  
clinical experience with, 694-695  
enteral nutrition, 696-697  
new directions in, 699-700  
parenteral nutrition, 697-699  
patient selection, 695  
protein degradation in, assessment, 690-692  
protein metabolism in, 687-688  
recovery following, dialysis and, 694  
renal replacement therapy in, 692-694  
Adenosine triphosphate (ATP), in energy expenditure, 589
- Adenovirus, diarrhea in AIDS due to, 550
- Adult respiratory distress syndrome (ARDS), infiltrates of, 264
- Aerosol therapy, 82-87
- Aerosolization process, 92
- Agitated patients in ICU without an artificial airway, evaluation of, 916-917  
sedation of, **931-936**. See also *Sedation, in ICU, of agitated patients without artificial airway*.
- Agitation. See also *Sedation*.  
causes, 915  
disorientation and, 915  
nighttime, sedation for, 795-797  
paradoxical, sedatives and, 931  
recurrent, problems related to, sedation for, 952  
as symptom, 914  
untreated pain and, 917-918
- AIDS. See *Acquired immunodeficiency syndrome*.
- Airway(s), anatomy of, 53-54

Airway(s) (*Continued*)

- artificial, absence of, sedation of agitated patients with, 913-936. See also *Sedation, in ICU, of agitated patients without artificial airway.*
- difficult, anatomic predictors of, 2-4
- evaluation and management, 1-27
- extubation of patient with, 21-23
- factors in, 2-7
- management, American Society of Anesthesiologists practice guidelines for, 7, 8
  - awake direct laryngoscopy, 11-12
  - awake intubation versus intubation under general anesthesia, 9-11
  - blind nasal intubation, 12
  - cricothyrotomy, 18-19
  - esophageal airways, 17-18
  - fiberoptic intubation, 12-13
  - illuminating intubating stylet in, 14-15
  - Laryngeal Mask Airway, 15-16
  - retrograde intubation, 13-14
  - spontaneous ventilation versus abolition of spontaneous ventilation, 11
  - strategies for, 7-19
  - surgical versus nonsurgical techniques, 9
  - tracheotomy, 18-19
  - transtracheal jet ventilation, 16-17
- prevalence, 2
- recognition of, 2-7
- esophageal obturator, in airway management, 59
- hypoxemia related to, causes, 32
- management. See *Airway management.*
- monitoring of, 57
- pediatric, management of, 63-64
- Airway management, emergency, 53-66
  - in asthmatics, 64
  - for cervical spine injuries, 63
  - in children, 63-64
  - cricothyrotomy, 58-59
  - drugs, 60-62
  - esophageal obturator airway in, 59
  - fiberoptic endoscopy, 60
  - for head trauma, 62-63
  - nasal airway, 56
  - nasotracheal intubation, 57-58
  - oral airway, 56
  - oral endotracheal approach, 56-57
  - orotracheal intubation, 57
  - postintubation essentials in, 58
  - PTV, 59
  - retrograde intubation, 60
  - tactile intubation, 60
  - immediate, 54-56
  - indications, 55
- Albumin, in infection, 580
  - in nutritional assessment, 611
- Alcohol withdrawal, benzodiazepines for, 868
  - sedatives and, 931-932
- Alfentanil, chemical structure of, 850
- in ICU, studies in evaluation of, 910
- Amino acids, branched-chain, in nutritional support, 639-640
  - in pulmonary function, 711
- loss of, in acute renal failure, 693
- metabolism of, in septic patients, 720-721
  - in nutritional support, 635-650
  - arginine, 643-645
  - branched-chain amino acids, 639-640
  - cysteine, 645
  - glutamine, 640-642
  - nonprotein metabolic pathways, 638
  - requirements, 636-639
  - tyrosine, 645
- requirements, in acute renal failure, 690, 692
  - in septic patients, 725-726
- Amnesia, benzodiazepines and, 863
- Amphotericin-B, aerosolized, 91
- Analgesia, benzodiazepines and, 865
- Analyzer(s), in mass spectrometry, types, 223-224
- Anesthesia/anesthetics, general, defined, 791
  - inhalational, in ICU, 887-902. See also *Inhalational anesthetic agents, in ICU.*
- Angiodysplasia, treatment, 359
- Angiography, in acute mesenteric ischemia, 490-491
- Antacids, diarrhea due to, 467
  - in prevention of stress-related upper gastrointestinal bleeding, 329-335
- Anthropometry, in nutritional assessment, 607-609
- Antibiotics, inhaled, 90-92
- Anticonvulsant(s), benzodiazepines as, 865
- Antral vascular ectasia, treatment, 359
- Anxiety, induction of, drugs associated with, 904
- Anxiolysis, benzodiazepines and, 863
- Aprotinin, for acute pancreatitis, 301
- Arginine, in nutritional support, 643-645
- Arm circumference measurements, in nutritional assessment, 608-609
- Arrhythmia(s), respiratory sinus, in sedation assessment, 818
- Arterial carbon dioxide pressure, and deadspace ventilation, 225-229
- Arteriovenous malformations (AVMs), treatment, 359
- Arthritis, in Crohn's disease, 526
- Ascites, in cirrhosis, 443-446
  - diagnosis, 444-445
  - large-volume paracentesis, 445-446

- pathogenesis, 443-444  
 peritoneovenous shunt, 446  
 transjugular intrahepatic portosystemic shunt, 446  
 treatment, 445  
 complications, metabolic and hormonal, 450-451
- Ascorbic acid, characteristics and interactions, 667-668
- Atracurium, 967, 969-970
- Atropine, in airway management, 62
- Auditory-evoked potentials (AEP), in sedation assessment, 819-822
- Autogenic drainage (AD), 90
- Awake direct laryngoscopy, for difficult airway, 11-12
- Awake fiberoptic intubation, 32-33
- Bacteria, diarrhea in AIDS due to, 552-553
- Bacterial infections, diarrhea in, treatment, 554-555
- Balloon tamponade, for variceal hemorrhage, 398
- Barbiturate(s), in ICU, 876-878  
 for sedation of agitated patients without artificial airway, 929
- Benzodiazepine(s), absorption of, 862  
 adverse effects, 1011<sup>1</sup>  
 in alcohol withdrawal, 868  
 distribution of, 862-863  
 drug interactions with, 868  
 duration of, 862, 864  
 elimination of, 863  
 in ICU, 829-835, 859-870  
 clinical uses, 866  
 complications, 985  
 concerns related to, 868  
 for sedation of agitated patients without artificial airway, 918-920, 928  
 onset of, 862, 864  
 pharmacodynamics, 863, 865-866  
 pharmacokinetics, 862-863  
 physiochemical properties of, 861
- Benzodiazepine agonists, 860, 862
- Benzodiazepine antagonists, 860, 862, 869
- Benzodiazepine receptors, 860, 861
- Beta-blockers, for esophagogastric varices, 435  
 in prevention of variceal hemorrhage, 404  
 in prevention of variceal hemorrhage recurrence, 399-400
- Bile leaks, 289-290
- Biliary tract diseases, 273-294  
 acalculous cholecystitis, 276-278  
 acute cholecystitis, 273-275  
 bile leaks, 289-290  
 gallstone pancreatitis, 286-289  
 obstructive cholangitis, 279-285
- Bioartificial liver devices, for fulminant hepatic failure, 427
- Biochemical tests, in nutritional assessment, 609-614
- Bioelectrical impedance, in nutritional assessment, 616-617
- Biotin, characteristics and interactions, 671
- Bispectral analysis, in sedation assessment, 812-817
- Bleeding, gastrointestinal, in AIDS, 546-548  
 lower intestinal, 369-389. See also *Hemorrhage, lower intestinal*.  
 upper intestinal, nonvariceal, 347-368.  
 See also *Gastrointestinal bleeding, upper, nonvariceal*.  
 stress-related, 325-327
- Blind nasal intubation, for difficult airway, 12
- Blood flow, collateral, in acute mesenteric ischemia, 483  
 intestinal, in acute mesenteric ischemia, 484-486
- Blood gas(es), arterial, monitoring of, 233-248  
 design constraints for, 241  
 errors of analysis and performance criteria, 235-236  
 instrument variability, 238  
 temperature correction, 236-237  
 value of, 238-246
- Blood gas sampling, arterial, 237-238
- Blood phase, in oxygen monitoring, 203-210
- Body composition, measurement, 616-617
- Body temperature, measurements of, 588  
 and metabolic rate, 190
- Bone marrow transplantation, mucosal injury due to, 364
- Branched-chain amino acids, in nutritional support, 639-640  
 in pulmonary function, 711
- Breathing, work of, 162  
 intrinsic PEEP, 163-164  
 mechanical, 162-163
- Bronchial hygiene therapy, 79-96  
 aerosol therapy, 82-87  
 consultation services for, 92-93  
 incentive spirometry, 79-80  
 IPPB, 81-82  
 prophylactic versus therapeutic, 79  
 protocols for, 92-93  
 suctioning in, 80-81
- Bronchoscope, flexible fiberoptic. See *Fiberscope*.
- Bronchoscopy, fiberoptic, through Laryngeal Mask Airway, 44-45  
 in ICU, 97-109  
 complications, 104-106

- Bronchoscopy (*Continued*)  
 contraindications, 106  
 diagnostic uses, 98-101  
 history of, 97-98  
 special uses, 103-104  
 therapeutic uses, 101-103
- Bronchopulmonary dysplasia, infants  
 with, nutritional management in, 773
- Bulb syringe, in endotracheal tube  
 placement, 21
- Burn(s), hypermetabolic response to, 735  
 incidence, 735  
 infection following, 737  
 systemic approach to, 735  
 victims of, children, nutritional support  
 for, 741-742  
 nutrient pharmacology in, 747-748  
 nutritional support for, 735-750  
   caloric, 740-741  
   factors affecting, 743  
   fats, 739-740  
   glucose, 739  
   goals, 738-739  
   lipids, 739-740  
   overfeeding, adverse effects, 742  
   protein, 739  
   route and timing of administration,  
     744-746
- Butyropherone(s), adverse effects, 1011  
 in ICU, complications, 986-987
- Calcium, in nutritional assessment, 628
- Calorie requirements, in burn patients,  
 740-741  
 in septic patients, 721-722
- Calorimetry, direct, measurement, 591  
 indirect, limitations of, 188-189  
 measurement, 591-593  
 practical considerations, 595-599
- Cancer, hepatocellular, in cirrhosis,  
 449-450
- Cannula(ae), nasal, 71-73
- Capnography, 219-232  
 clinical application of, 224  
 data display in, 229-231  
 mass spectrometry for, 221-225  
 technical aspects of, 219-221
- Carbohydrate(s), in acute renal failure, 699  
 in infection, 578  
 during liver failure, 680  
 metabolism of, in acute renal failure, 689  
 in septic patients, 718-719  
 oxidation, measurement, 593  
 for preterm neonates with multisystem  
 organ failure/systemic inflamma-  
 tory response syndrome, 762-763  
 requirements, in septic patients, 722-723
- Carbon dioxide, excreted, in endotracheal  
 tube placement, 20
- systemic circulation and, 229
- Cardiac disease, and metabolic rate, 191
- Cardiovascular system, benzodiazepine  
 effects on, 865  
 diseases of, difficult airway due to, 5-6  
 opioid effects on, 857  
 problems related to, sedation for, 949-  
 950
- $\beta$ -Carotene, characteristics and  
 interactions, 666
- Cellular metabolism, control of, sedation  
 for, 797-798
- Central nervous system (CNS),  
 benzodiazepine effects on, 863-864  
 opioid effects on, 857  
 problems related to, sedation for, 950-  
 951
- Cerebral edema, in fulminant hepatic  
 failure, 419  
 management, 424-425
- Cervical flexion-extension, difficult airway  
 due to, 4
- Cervical spine injuries, airway  
 management in, 63
- Charcot's triad, criteria, 260
- Chemotherapeutic agents, diarrhea due to,  
 467-468
- Chest physical therapy, 87-90  
 contraindications, 89-90  
 indications, 89
- Chest tube(s), 120-126
- Chest tube drainage, 111-126
- Children, airway management in, 63-64  
 burns in, nutritional support for, 741-  
 742  
   pulmonary failure in, 707
- Chlordiazepoxide, 859
- Cholangiohepatitis, oriental, 279-280
- Cholangitis, obstructive, 279-285  
 causes, 279-280  
 diagnosis, 280-281  
 endoscopic drainage in, 283-285  
 mortality of, 279  
 presentation, 279  
 treatment, 281-285
- Cholecystitis, acalculous, 276-277  
 in AIDS, 277-278  
 described, 276  
 diagnosis, 277-278  
 signs and symptoms, 276-277  
 treatment, 278
- acute, 273-275  
 causes, 273  
 diagnosis, 273-274  
 treatment, 274-275  
 ultrasonography in, 260, 261
- Choledocholithiasis, risk factors for, 279
- Choline, for multisystem organ failure/  
 systemic inflammatory response  
 syndrome, 768

- Chromium, characteristics and interactions, 657-658
- Chronic obstructive pulmonary disease (COPD), malnutrition in, 706-707
- Cimetidine, diarrhea due to, 467
- for nosocomial pneumonia, 340-341
- in prevention of stress-related upper gastrointestinal bleeding, 333-335
- Circadian changes, and metabolic rate, 189
- Circulation, collateral, in acute mesenteric ischemia, 482-483
- systemic, CO<sub>2</sub> and, 229
- Cirrhosis, 431-463
- ascites in, 443-446
- causes, 431-432
- clinical features, 431-432
- coagulopathy in, 448-449
- complications, 433-451
- esophago gastric varices in, treatment, 433-441
- gastric varices in, 440
- glucose intolerance in, 450-451
- hepatic encephalopathy in, 441-443
- hepatocellular carcinoma in, 449-450
- hepatorenal syndrome in, 447-448
- hypoglycemia in, 451
- liver transplantation for, 452, 454-455
- osteodystrophy in, 451
- portal hypertensive gastropathy in, treatment, 440-441
- sequelae and prognostic features, 432-433
- spontaneous bacterial peritonitis, 446-447
- Clostridium difficile*, and AIDS, 541-542
- CMV. See *Cytomegalovirus*.
- CNS. See *Central nervous system*.
- Coagulopathy, in cirrhosis, 448-449
- in fulminant hepatic failure, management, 421-422
- Colitis, CMV, in AIDS, 535-538
- fulminant, and toxic megacolon, in Crohn's disease, 524-525
- in ulcerative colitis, 514-518
- infectious, lower gastrointestinal bleeding due to, 381
- radiation, lower gastrointestinal bleeding due to, 381
- ulcerative. See *Ulcerative colitis*.
- Collateral blood flow, in acute mesenteric ischemia, 483
- Collateral circulation, in acute mesenteric ischemia, 482-483
- Colon, anatomy of, 375-376
- Compliance curve, clinical, calculation of, 159-162
- Compounds, high energy, 589-590
- COPD. See *Chronic obstructive pulmonary disease*.
- Copper, characteristics and interactions, 655-656
- Creatinine-height index, in nutritional assessment, 614
- Cricothyrotomy, in airway management, 58-59
- for difficult airway, 18-19
- Crohn's disease, 513, 519-527
- abscesses in, 522-523
- arthritis in, 526
- extraintestinal complications, 525-526
- features, 519
- fulminant colitis and toxic megacolon in, 524-525
- gastroduodenal, 520-521
- hemorrhage in, 524
- of large bowel, 522
- ocular manifestations in, 526
- perforation in, 524
- of small bowel, 521
- urologic manifestations in, 526-527
- Cryptosporidiosis, in diarrhea, treatment, 554
- Cysteine, for multisystem organ failure/systemic inflammatory response syndrome, 767
- in nutritional support, 645
- Cytokine(s), infection and, 577-578, 581
- in multisystem organ failure/systemic inflammatory response syndrome, 758
- Cytomegalovirus (CMV) colitis, in AIDS, 535-538
- Cytomegalovirus (CMV) esophagitis, in AIDS, 538-539
- Cytomegalovirus (CMV) infection, diarrhea in, treatment, 553-554
- Delirium, drugs causing, 905
- DEXA. See *Dual-energy x-ray absorptiometry*.
- Diabetes, infants of mothers with, nutritional management in, 775-776
- Dialysis, effect on recovery of renal function, 694
- Diarrhea, in AIDS, causes, 548-553
- treatment, 553-556
- HIV-related, treatment, 555-556
- in ICU patients, 465-477
- causes, 466-473
- clinical approach to, 473-474
- incidence, 465
- Diazepam, chemical structure of, 862
- for sedation of agitated ICU patients without artificial airway, 928
- Dieulafoy's lesion, treatment, 363
- Disorientation, agitation due to, 915
- Diverticulum(a), anatomy of, 375-376
- colonic, lower gastrointestinal bleeding due to, 375-380
- clinical features, 378-379

- Diverticulum(a) (*Continued*)  
 epidemiology, 376-377  
 evaluation, 379-380  
 pathophysiology, 377-378  
 treatment, 379-380  
 Meckel's, lower gastrointestinal bleeding due to, 383  
 Doxacurium, 967, 971  
 Droperidol, in ICU, 879  
 Drug(s), in airway management, 60-62  
 diarrhea due to, 466-468  
 and metabolic rate, 192  
 metabolism of, altered, in advanced liver disease, 451-452, 453  
 psychosis and delirium due to, 905  
 Dry powder inhaler, 85  
 Dual-energy x-ray absorptiometry (DEXA), in nutritional assessment, 617-619  
 Duplex scanning, in acute mesenteric ischemia, 490  
 Dye(s), in oxygen monitoring, 206-207  
 Dyshemoglobinemias, in oxygen monitoring, 205-207
- Ectasia(s), colonic vascular, lower gastrointestinal bleeding due to, 370-375  
 clinical features, 372-373  
 diagnosis, 373-374  
 epidemiology, 372  
 histopathology, 371  
 pathophysiology, 371-372  
 treatment, 374-375  
 Edema, cerebral, in fulminant hepatic failure, 419  
 management, 424-425  
 Elastance, monitoring of, 153-154  
 Electrical stimulation, of ulnar nerve, in nutritional assessment, 621  
 Electroencephalography (EEG), in sedation assessment, 807-817  
 bispectral analysis, 812-817  
 neurophysiologic basis of, 807-808  
 processed EEG signals, 808-812  
 Electroencephalography (EEG) signals, processed, 808-812  
 frequency-domain methods, 810-812  
 time-domain methods, 808-810  
 Electrolyte(s), in acute renal failure, 689  
 in nutritional assessment, 625-629  
 Embolus(i), superior mesenteric artery, management, 496-497  
 Encephalopathy, in fulminant hepatic failure, management, 424-425  
 hepatic, in cirrhosis, 441-443  
 management, 442-443  
 pathogenesis, 441-442  
 Endobronchial intubation, 47-48  
 Endobronchial tube, placement of, detection of, 21  
 Endoscopic sclerotherapy, for esophagogastric varices, 436-437  
 in prevention of variceal hemorrhage recurrence, 402-403  
 for variceal hemorrhage, 397-398  
 Endoscopic therapy, fiberoptic, in airway management, 60  
 in gallstone pancreatitis, 287-289, 290  
 Endoscopic variceal ligation, for esophagogastric varices, 437, 438  
 in prevention of variceal hemorrhage recurrence, 403  
 for variceal hemorrhage, 398-399  
 Endoscopy mask technique, for the unconscious patient, 41-42  
 Endotoxins, infection due to, 576-577  
 Endotracheal intubation, oral, 56-57  
 Endotracheal tube, fiberoptic changing of, 45-48  
 placement of, confirmation of, 19-21  
 Energy, requirements, in acute renal failure, 689-690  
 in septic patients, 721-722  
 Energy expenditure, 162, 184  
 in acute renal failure, 686-689  
 components, 598  
 cost of doing work, 589-590  
 isovolumetric, 164  
 measurement, 590-595  
 direct calorimetry, 591  
 estimation of carbohydrate oxidation in vivo, 593  
 Fick principle, 595  
 gluconeogenesis, 594  
 indirect calorimetry, 591-593  
 practical considerations, 595-599  
 ketone body metabolism, 594-595  
 lipogenesis, 594  
 and nitrogen excretion, relationship between, 572  
 resting, estimation of, 186  
 theories and assumptions on, 587-601  
 Energy metabolism, defined, 587  
 Enflurane, in ICU, 890-891  
 Enteral nutrition, diarrhea due to, 468-471  
 Episcleritis, in Crohn's disease, 526  
 Erosion(s), gastric, treatment, 358-359  
 Esophageal disease, in AIDS, 533-534  
 Esophageal obturator airway, in airway management, 59  
 for difficult airway, 17-18  
 Esophagitis, CMV, in AIDS, 538-539  
 Esophagus, staple transection of, for variceal hemorrhage, 399  
 Etomidate, in ICU, complications, 987  
 for sedation of agitated patients without artificial airway, 929  
 Evoked potentials, in sedation assessment, 818-822

- Extrapyramidal reactions, sedatives and, 931
- Fat(s), in burn patients, 739-740  
     during liver failure, 680  
     for multisystem organ failure/systemic inflammatory response syndrome, 764-766
- Feed/fast cycle, insulin in, 570-571  
     metabolism of, 570-571
- Fentanyl, for ICU sedation, 841, 842  
     pharmacokinetics, 857
- Fiberoptic bronchoscopy, through  
     Laryngeal Mask Airway, 44-45
- Fiberoptic cart, 34
- Fiberoptic chemical sensor systems, characteristics, 245
- Fiberoptic endoscopy, in airway management, 60
- Fiberoptic orotracheal intubation, in conscious patients, 36-37
- Fiberscope, components of, 30  
     indications, 31  
     role of, 29-51  
     uses, 29-51
- Fick method, in metabolic rate measurement, 171
- Fick principle, 595
- Fish oil, for multisystem organ failure/systemic inflammatory response syndrome, 769-770
- Fistula(s), aortoenteric, lower  
     gastrointestinal bleeding due to, 383-384  
     treatment, 363  
     pancreatic, 319-320
- Flexible fiberoptic bronchoscope. See *Fiberscope*.
- Fluid(s), pericellular, changes in, and metabolic regulation, 581-582
- Flumazenil, 869  
     chemical structure of, 862
- Folic acid, characteristics and interactions, 671
- Forced expiratory technique (FET), 90
- Foscarnet, for diarrhea, 553-554
- Fourier's law of heat flow, 588
- Free fatty acids, in septic patients, 719-720
- Fulminant hepatic failure, 415-430  
     causes, 416-418  
     cerebral edema in, 419  
         management, 424-425  
     clinical features, 418-419  
     defined, 416  
     diagnosis, criteria in, 415  
     encephalopathy in, management, 424-425  
     hepatic dysfunction in, 418  
     infection in, 418  
         management, 422-423  
     liver transplantation for, 419-421  
     management, 421-426  
         coagulopathy, 421-422  
         experimental, 426-427  
     renal failure in, management. See *Kidney failure*.  
     syndrome of multiple organ failure in, 419  
         management, 423-424
- Gallstone disease, in Crohn's disease, 525-526
- Gallstone pancreatitis, 286-289. See also *Pancreatitis, gallstone*.
- Ganciclovir, for diarrhea, 553-554
- Gas exchange method, in metabolic rate measurement, 171-173
- Gas phase, in oxygen monitoring, 200-203
- Gastritis, stress, erosive, treatment, 359-360  
     treatment, 360-361
- Gastrointestinal bleeding. See also *Hemorrhage*.  
     in AIDS, 546-548  
     upper, nonvariceal, 347-368  
         aortoenteric fistulas, 363  
         background material, 347-348  
         bone marrow transplantation and, 364  
         causes, 361-364  
         control measures, 354  
         Dieulafoy's lesion, 363  
         erosions, 358-359  
         evaluation, 349-352  
         future outlook concerning, 347-348  
         hemobilia, 363  
         ICU admission criteria, 350-351  
         incidence, 347  
         initial management, 349-354  
         Mallory-Weiss tear, 357-358  
         mortality from, 347  
         patient history in, 348-349  
         peptic ulcer, 355-357  
         physical examination, 348-349  
         stress erosive gastritis, 359-360  
         stress gastritis, treatment, 360-361  
         vascular anomalies, 359  
         risk factors for, 327-329  
         stress-related, 325-327. See also *Mucosal disease, stress-related*.
- Gastrointestinal system, emergencies related to, in AIDS, 531-560. See also *Acquired immunodeficiency syndrome (AIDS), gastrointestinal emergencies in*.  
     opioid effects on, 858  
     Glasgow Coma Scale, 804, 805



- Glucocorticoids, effect on insulin, 576  
 Gluconeogenesis, 594  
 Glucose, in burn patients, 739  
   loss of, in acute renal failure, 693  
   uptake, noninsulin-mediated versus insulin-mediated, 575  
 Glucose intolerance, in cirrhosis, 450-451  
 Glutamine, for multisystem organ failure/  
   systemic inflammatory response  
   syndrome, 768  
   in nutritional support, 640-642  
 Growth factors, in acute renal failure, 700  
   peptide, for multisystem organ failure/  
   systemic inflammatory response syn-  
   drome, 768-769  
 Gut priming, for multisystem organ  
   failure/systemic inflammatory  
   response syndrome, 770-772
- Half-life, 829  
 Haloperidol, in ICU, 879-880  
   for sedation of agitated patients without  
   artificial airway, 928  
   studies in evaluation of, 910  
 Halothane, in ICU, 890  
 Head trauma, rapid-sequence intubations  
   in, 62-63  
 Heat flow, Fourier's law of, 588  
 Heat gain, 588  
 Heat loss, 588  
 Heat production, formula, 587  
 Hemobilia, treatment, 363  
 Hemodialysis, nutritional, 699-700  
   as stimulus for protein catabolism in  
   acute renal failure, 693  
 Hemoglobin extinction curves, 204  
 Hemoglobin saturation measurements, in  
   oxygen monitoring, 204-205  
 Hemoptysis, causes, 99  
 Hemorrhage. *See also Bleeding.*  
   in acute pancreatitis, 313-317  
   in Crohn's disease, 524  
   lower intestinal, 369-389  
     aortoenteric fistulas and, 383-384  
     causes, 370-384  
     colonic diverticula and, 375-380  
     colonic ischemia and, 380-381  
     colonic vascular ectasia and, 370-375  
     defined, 369  
     evaluation, 384-387  
     hemorrhoids and, 382  
     infectious colitis and, 381  
     inflammatory bowel disease and, 380  
     Meckel's diverticulum and, 383  
     neoplasms and, 382  
     radiation colitis and, 381-382  
     rectal ulcers and, 383  
     rectal varices and, 382  
     treatment, 384-387  
   ulcerative colitis and, 518-519  
   variceal, 391-414  
     active, treatment, 392-399  
       balloon tamponade, 398  
       decreasing or interrupting variceal  
       blood flow, 397-399  
       emergent shunt surgery, 395-397  
       endoscopic sclerotherapy, 397-398  
       endoscopic variceal ligation, 398-  
       399  
       esophageal transection, 399  
       pharmacologic, 393-395  
       reducing portal pressure, 393-397  
     approach to patient with, 405-406  
     prevention, 403-405  
       decreasing or interrupting variceal  
       blood flow, 405  
       endoscopic sclerotherapy, 405  
       pharmacologic, 404  
       reducing portal pressure, 404  
       shunt surgery, 404-405  
     prevention of rebleeding, 399-403  
       decreasing or interrupting variceal  
       blood flow, 402-403  
       endoscopic sclerotherapy, 402-403  
       pharmacologic, 399-401  
       reducing portal pressure, 399-402  
       shunt surgery, 401-402  
       variceal ligation, 403  
     treatment, 391-392  
 Hemorrhoids, lower gastrointestinal  
   bleeding due to, 382  
 Hepatic encephalopathy, in cirrhosis,  
   441-443  
 Hepatobiliary disease, in AIDS, 544-546  
 Hepatocellular carcinoma, in cirrhosis,  
   449-450  
 Hepatocyte transplantation, for fulminant  
   hepatic failure, 427  
 Hepatorenal syndrome, in cirrhosis,  
   447-448  
   defined, 447  
 Herpes virus infection, diarrhea in AIDS  
   due to, 551  
 High energy compounds, 589-590  
 Histamine-blocking agents, diarrhea due  
   to, 467  
 Histamine type 2-receptor antagonists, in  
   prevention of stress-related upper  
   gastrointestinal bleeding, 329-335  
 Homeostasis, thermal, 587-589  
 Human immunodeficiency virus (HIV)  
   infection, diarrhea in, treatment,  
   555-556  
 Human immunodeficiency virus (HIV)  
   enteropathy, diarrhea in AIDS due to,  
   553  
 Humidification process, in aerosol therapy,  
   85-86



- Hyperglycemia, in cirrhosis, 450-451  
 fasting versus postprandial, 575  
 Hypermetabolism, causes, 183  
 Hypertension, portal, defined, 433  
 Hyperthermia, described, 588  
 Hypoglycemia, in cirrhosis, 451  
 Hypometabolism, causes, 183  
 Hypothermia, described, 588  
 Hypoxemia, airway-related, causes, 32  
   causes, 68-69  
   defined, 68  
   described, 69  
 Hypoxia, oxygen therapy for, 64
- ICU. See *Intensive care unit*.
- Illuminating intubating stylet, for difficult airway, 14-15
- Immobility, sedatives and, 931
- Immunologic function, in nutritional assessment, 614-615
- In vivo neutron activation analysis (IVNAA), in nutritional assessment, 619
- Indirect calorimetry, limitations of, 188-189
- Infection(s). See also specific types.  
 albumin in, 580  
 bacterial, diarrhea in, treatment, 554-555  
 in burn patients, 737  
 carbohydrates and, 578  
 cytokines and, 577-578, 581  
 diarrhea due to, 471-472  
 endotoxins and, 576-577  
 in fulminant hepatic failure, 418  
   management, 422-423  
 metabolic response to, 576-582  
 pancreatic, in acute pancreatitis, medical management, 302-303
- Inflammation, prostaglandins in, 579
- Inflammatory bowel disease, emergencies in, 513-529  
   Crohn's disease, 513  
   ulcerative colitis, 513  
   lower gastrointestinal bleeding due to, 380
- Infrared carbon dioxide light absorption, 219-221
- Inhalational anesthetic agents, in ICU, 887-902  
   atmospheric pollution with, 897  
   complications, 987-988  
   equipment required for, 895-896  
   practical considerations with, 894-895  
   scavenging in, 896-897  
   for sedation of agitated patients  
     without artificial airway, 930  
   specific agents, 889-892  
   intravenous agents and, pharmacologic differences between, 888
- Inhaled antibiotic therapy, 90-92
- Inhalers, dry powder, 85  
   metered-dose, 82-85
- Injury(ies), metabolic response to, 571-576
- Insulin, in feed/fast cycle, 570-571  
   glucocorticoid effects on, 576
- Insulin-like growth factor 1, in nutritional assessment, 612-613
- Insulin resistance, 575  
   defined, 574-575
- Intensive care unit (ICU), bronchoscopic procedures in, 97-109  
   costs of, 1005-1007  
   diarrhea in, 465-477. See also *Diarrhea*, in ICU patients.  
   drug-usage patterns in, 1007-1010  
   sedation in. See *Sedation*, in ICU.
- Interleukin-1, infection and, 577-578, 581
- Intermittent positive pressure breathing (IPPB), 81-82
- Intestinal infarction, intramural gas in, 264
- Intrapulmonary shunting, defined, 68
- Intrauterine growth retardation (IUGR), infants with, nutritional management in, 776-778
- Intubation, blind nasal, for difficult airway, 12  
   endobronchial, 47-48  
   endotracheal, oral, 56-57  
   failed, prevalence, 1-2  
   fiberoptic, awake, 32-33  
     for difficult airway, 12-13  
   nasotracheal, 57-58  
   oro-tracheal, 57  
     fiberoptic, in a conscious patient, 36-37  
   rapid-sequence, in head trauma, 62-63  
     of the unconscious or anesthetized patient, 41  
   retrograde, in airway management, 60  
     for difficult airway, 13-14  
   tactile, in airway management, 60  
   tracheal. See *Tracheal intubation*.
- IPPB. See *Intermittent positive pressure breathing*.
- Iron, characteristics and interactions, 659-660
- Ischemia, colonic, lower gastrointestinal bleeding due to, 380-381  
   mesenteric. See *Mesenteric ischemia*.
- Ischemic bowel, diarrhea due to, 472
- Isoflurane, in ICU, 891-892  
   advantages, 898  
   atmospheric pollution with, 897  
   benefits, 897  
   disadvantages, 897-898  
   efficacy and safety of, 892-894  
   practical considerations with, 894-895  
   scavenging with, 896-897
- Isospora belli*, infection with, diarrhea in, treatment, 554

- Isovolumetric energy expenditure, 164
- Kaposi's sarcoma, in AIDS, 542-544  
bleeding due to, 547-548
- Ketamine, for sedation of agitated ICU patients without artificial airway, 929-930
- Ketone body metabolism, 594-595
- Kidney failure. *See also Acute renal failure.*  
in fulminant hepatic failure, management, 423  
problems related to, sedation for, 951-952
- Krebs cycle, 587
- Lambert-Beer law, 203
- Laparoscopy, in acute mesenteric ischemia, 490
- Laparotomy, for acute mesenteric ischemia, 494-495
- Large bowel, Crohn's disease of, 522
- Laryngeal Mask Airway (LMA), for difficult airway, 15-16  
fiberoptic bronchoscopy through, 44-45  
fiberoptic intubation through, of the unconscious or anesthetized patient, 42-44
- Laryngoscopy, awake direct, for difficult airway, 11-12
- Leukocyte(s), neuromuscular blocking agents and, 998
- Light-emitting diode center wavelength variability, in oxygen monitoring, 207
- Light wand, for difficult airway, 14-15
- Lipids, in acute renal failure, 699  
in burn patients, 739-740  
metabolism of, in acute renal failure, 689  
in septic patients, 719-720  
requirements, in septic patients, 723-725
- Lipogenesis, 594
- Liver disease, advanced, altered drug metabolism in, 451-452, 453  
alterations of thyroid hormone metabolism in, 451  
chronic, complications, 431-463. *See also Cirrhosis.*  
with fulminant presentation, causes, 416  
nutritional assessment, 676-677  
problems related to, sedation for, 951
- Liver failure, clinical presentation, 675  
malnutrition in, 675, 676  
nutritional support during, 675-683  
carbohydrates, 680  
fats, 680  
micronutrients, 680  
overview, 677-679  
proteins, 679-680  
vitamins, 680
- Liver transplantation, in cirrhosis, 452, 454-455  
contraindications, 454-455  
for fulminant hepatic failure, 419-421  
indications, 452, 454
- Lorazepam, chemical structure of, 862  
in ICU, 833-835, 836  
for sedation of agitated patients without artificial airway, 928  
studies in evaluation of, 910
- Magnesium, characteristics and interactions, 652-655  
in nutritional assessment, 627-628
- Mallampati classification, 3
- Mallory-Weiss tear, treatment, 357-358
- Malnutrition, in acute renal failure, causes, 688  
prehospitalization, in liver failure patients, 675, 676  
in pulmonary failure, 705-708  
acute, 707  
chronic, 706  
COPD, 706-707  
effects, 708  
in neonates, 707
- Manganese, characteristics and interactions, 658-659
- Mass spectrometers, in oxygen monitoring, 202-203
- Mass spectrometry, 221-225
- Maximum voluntary grip strength, in nutritional assessment, 621
- Mechanical ventilation, metabolic measurements during, 174-181  
sedation during, 792-795, 937-955  
benefits, 937-941  
for cardiovascular problems, 949-950  
for CNS problems, 950-951  
duration requirements, 943-948  
indications, 941-943  
in kidney failure, 951-952  
in liver disease, 951  
monitoring level of, 943  
for recurrent agitation, 952  
in respiratory failure, 948-949  
selection of agents, 941
- Meckel's diverticulum, lower gastrointestinal bleeding due to, 383
- Medicolegal issues, sedatives and, 931
- Megacolon, toxic. *See Toxic megacolon.*
- Membranes, gatekeeping property of, 578-579
- Meperidine, chemical structure of, 850  
pharmacokinetics, 856-857
- Mesenteric ischemia, acute, 479-512

- causes, arterial, 480-481
  - venous, 481
- cellular response to, 487
- clinical response to, 488
- collateral circulation in, 482-483
- complications, 498-499
- demographics of, 479-480
- diagnosis, 488-491
- effect on mucosal barrier, 488
- intestinal blood flow control in, 484-486
- laboratory signs, 489-490
- management, operative, 494-495
  - principles of, 491-494
- mesenteric vasoconstriction in, 486-487
- microcirculation and collateral flow in, 483
  - nonocclusive, management, 497
  - pathophysiology, 481-488
  - physiologic considerations in, 483
  - postoperative care, 495
  - radiographic signs, 490
  - results, 499-500
  - signs and symptoms, 488-489
  - superior mesenteric artery embolus, management, 496-497
  - types, 480-481
- acute superior mesenteric artery thrombosis in, management, 497-498
- Mesenteric venous thrombosis, 500-509
  - causes, 501-502
  - clinical manifestations, 502-504
  - demographics of, 501
  - diagnosis, 504-507
  - management, 507-509
  - natural history of, 502
- Metabolic rate, calculation of, 183-185
  - factors influencing, 189-192
  - measurement of, 169-197
    - clinical applications of, 183-188
    - historical overview, 169-170
    - interpretation of, 181-183
    - during mechanical ventilation, 174-181
  - methods of, 170-173
- Metabolic regulation, sites of, 581-582
- Metabolic response, 569-585. See also *Metabolism*.
  - in acute renal failure, 686-694
  - to infection, 576-582
  - to injury, 571-576
  - history, 574
- Metabolic state, 185-187
- Metabolism, in acute illness, 604
  - cellular, control of, sedation for, 797-798
  - of the feed/fast cycle, 570-571
- Metered dose inhalers, 82-85
- Metocurine, 967, 970
- Microcirculation, in acute mesenteric ischemia, 483
  - changes in, and metabolic regulation, 581-582
- Microminerals, 652-655
- Micronutrients, 651-673
  - assessment, in nutritional assessment, 621-625, 626, 627
  - during liver failure, 680
  - minerals, 651-662
- Microsporidiosis, diarrhea in, treatment, 554
- Midazolam, chemical structure of, 862
  - in ICU, 829-833
    - for sedation of agitated patients without artificial airway, 928
    - studies in evaluation of, 908-909
- Minerals, 651-662
  - in acute renal failure, 698-699
  - for multisystem organ failure/systemic inflammatory response syndrome, 766-767
  - requirements, in septic patients, 726-727
- Misoprostol, in prevention of stress-related upper gastrointestinal bleeding, 336
- Mivacurium, 966-969
- Molybdenum, characteristics and interactions, 661
- Morphine, chemical structure of, 850
  - in ICU, 839-841
  - pharmacokinetics, 856
- Mucosal disease, stress-related, 323-345
  - causes, 323-325
  - pathogenesis, 329
  - prevention, 329-336
- Multiple organ failure syndrome, in fulminant hepatic failure, 419
  - management, 423-424
- Multisystem organ failure/systemic inflammatory response syndrome, in preterm infants, 751-784
  - cellular and cytokine-regulated responses, 758
  - described, 754-758
  - nutritional management, 758-778
    - carbohydrates, 762-763
    - complications, 759-767
    - conditionally essential nutrients, 767-768
    - enteral and parenteral nutrition, 772
    - fats, 764-766
    - fish oil, 769-770
    - gut priming, 770-772
    - medium-chain triglycerides, 769-770
    - minerals, 766-767
    - peptide growth factors, 768-769
    - proteins, 763-764
    - vitamins, 766-767
    - water, 759-762
- Myocardial ischemia, prevention, sedation for, 798-801

- Nasal cannula, 71-73
- Nasogastric tube, placement of, fiberoptic-aided, 47
- Nasopharyngeal airway, emergency management of, 56
- Nasotracheal intubation, 57-58
- Near-infrared spectroscopy, 210
- Nebulizers, oxygen, 75-76  
small-volume, 82-85
- Neonates, preterm, bronchopulmonary dysplasia in, nutritional management in, 773  
of diabetic mothers, nutritional management in, 775-776  
with intrauterine growth retardation, nutritional management in, 776-778  
metabolism of, critical oxygen delivery effects on, 751-754  
multisystem organ failure/systemic inflammatory response syndrome in, 751-784. See also *Multisystem organ failure/systemic inflammatory response syndrome, in preterm infants.*  
short bowel syndrome in, nutritional management in, 773-775  
pulmonary failure in, 707
- Neoplasms, lower gastrointestinal bleeding due to, 382
- Neostigmine, in airway management, 62
- Nerve(s), ulnar, electrical stimulation of, in nutritional assessment, 621
- Neural network analysis, in sedation assessment, 818
- Neuroleptic(s), in ICU, 878-880  
for sedation of agitated patients without artificial airway, 928
- Neuroleptic malignant syndrome, 879, 928
- Neuromuscular blocking agents, in airway management, 61-62  
costs of, specific drug doses, 1016  
excretion of, 964  
in ICU, 957-981  
assessment and monitoring of, 973-975  
classification of, 962  
clinical considerations, 962  
in closed head injuries, 997  
CNS effects, 997-998  
complications, 983-1003. See also *specific agents, e.g., Propofol.*  
pharmacologic problems, 989-991  
physiologic changes, 991-992  
toxic side effects, 992-997  
future directions with, 977  
long-term use of, controversies regarding, 997-998  
selection of, 971-973  
termination of, 975-976  
uses, 958  
intermediate-acting, 969-970  
leukocyte activity and, 998  
long-acting, 970-971  
metabolism of, 964  
pharmacokinetics of, 964-965  
short-acting, 966-969  
speed of onset of, 963-964  
structure of, 962-963  
ultra-short-acting drugs, 965-966
- Neuromuscular junction, 959
- Neuromuscular transmission, 959-962
- Niacin, characteristics and interactions, 669-670
- Nicotinic acetylcholine receptor (AChR), 960
- Nitrates, organic, with vasopressin, for variceal hemorrhage, 393-394  
in prevention of variceal hemorrhage, 404  
in prevention of variceal hemorrhage recurrence, 400-401
- Nitrogen, and energy expenditure, relationship between, 572
- Nitrogen balance, in nutritional assessment, 613-614
- Nitrous oxide, in ICU, 889-890
- Normal growth ex utero, defined, 759
- Normothermia, 588-589
- Nutrient(s), pharmacology, 747-748  
requirements, in acute renal failure, 689-690
- Nutrition, assessment, 603-634. See also *Nutritional assessment.*  
enteral, in acute renal failure, 696-697  
diarrhea due to, 468-471  
parenteral, in acute renal failure, 697-699
- Nutritional assessment, 603-634  
albumin tests in, 611  
anthropometry, 607-609  
arm circumference measurement, 608-609  
biochemical tests, 609-614  
body composition measurement in, 616-617  
calcium, 628  
creatinine-height index in, 614  
dual-energy x-ray absorptiometry in, 617-619  
electrolytes, 625-629  
immunologic function tests in, 614-615  
insulin-like growth factor 1 tests in, 612-613  
magnesium, 627-628  
micronutrients, 621-625, 626, 627  
multiparameter, 615-616  
nitrogen balance/urine nitrogen tests in, 613-614  
of patients with severe liver disease, 676-677

- phosphate, 628-629  
 physiologic function tests in, 619-621  
 plasma protein tests in, 609-611  
 pre-albumin tests in, 612  
 skinfold thickness measurement, 607-609  
 subjective global assessment, 605-607  
 transferrin tests in, 611  
 Nutritional support, amino acids in, 635-650. See also *Amino acids, in nutritional support*.  
 for burn patients, 735-750. See also *Burn(s), victims of, nutritional support for*.  
 during liver failure, 675-683. See also *Liver failure, nutritional support during*.  
 in multisystem organ failure/systemic inflammatory response syndrome, in preterm infants, 758-778  
 proteins in, 635-650  
 during pulmonary failure, 708-713. See also *Pulmonary failure, nutritional support in*.  
 in renal failure, 685-704. See also *Acute renal failure, nutritional support in*.  
 of septic patients, 717-733. See also under *Sepsis*.
- Observer's Assessment of Alertness/Sedation (OAA/S) Scale, 806  
 Obstructive cholangitis, 279-285. See also *Cholangitis, obstructive*.  
 Octreotide, and somatostatin, for variceal hemorrhage, 394-395  
 Omega-3 Fatty acids, in pulmonary function, 711  
 Omeprazole, in prevention of stress-related upper gastrointestinal bleeding, 335-336  
 Operational verification procedure (OVP), 133-134  
 Opioid(s), adverse effects, 1011  
 benzodiazepines and, interactions between, 868  
 chemical structure of, 850  
 classification of, 851  
 endural/intrathecal, 855-856  
 in ICU, 838-841, 849-859  
 clinical uses, 858-859  
 patient-controlled analgesia with, 853-854  
 for sedation of agitated patients without artificial airway, 927-928  
 pharmacodynamics, 857-858  
 pharmacokinetics, 856-857  
 routes of administration of, 853-856  
 Opioid antagonists, 859  
 Opioid receptors, clinical responses of, 852  
 in ICU, 850-852  
 Optical sensor, absorbance-based, diagram of, 242  
 Organ dysfunction syndrome, 257, 264  
 Oropharyngeal airway, emergency management of, 56  
 Orotracheal intubation, 57  
 Osteodystrophy, in cirrhosis, 451  
 Ovassapian fiberoptic intubating airway, 35  
 Oxygen, clinical measurement of, 200-213  
 Oxygen consumption, reduction of, sedation during mechanical ventilation and, 937-940  
 Oxygen controllers, 76-77  
 Oxygen delivery, to preterm neonates, metabolism effects, 751-754  
 Oxygen delivery devices, 71-76  
 Oxygen delivery systems, 69-71  
 Oxygen masks, 73-74  
 Oxygen nebulizers, 75-76  
 Oxygen tension, monitoring of, 210-212  
 Oxygen therapy, 67-78  
 complications, 77-78  
 indications, 64  
 Oxygenation, monitoring of, noninvasive, 199-217  
 accuracy, 208  
 applications, 208-209  
 blood and tissue phase, 203-210  
 complications, 208  
 gas phase, 200-203  
 hemoglobin saturation measurements, 203-205  
 light-emitting diodes, 207  
 limitations of, 205-207  
 mass spectrometers, 202-203  
 near-infrared spectroscopy, 209-210  
 Raman scattering, 201-202  
 response to, 208  
 signal artifact, 207-208  
 transcutaneous, index of, 211
- Pain, abdominal, in AIDS, 532-533  
 untreated, of agitated patients without artificial airway in ICU, 917-918  
 Pancreas, abscess of, 318  
 fistula of, 319-320  
 infection of, in acute pancreatitis, medical management, 302-303  
 pseudocyst of, 318-319  
 Pancreatic fluid collections, in acute pancreatitis, medical management, 303-305  
 Pancreatitis, acute, 311-322  
 case report, 314-316  
 complications, 295, 300

Pancreatitis (*Continued*)

- medical management, 302-305
- diagnosis, 312-313
- differential diagnosis, 312
- management, medical, 295-309
  - drugs, 301
  - supportive strategies, 299-300
- modified Glasgow criteria, 297
- mortality of, 295
- pancreatic abscess in, 318
- pathophysiology, 311-312
- Rabeneck clinical prognostic staging system, 298
- Ranson criteria, 296
- resuscitation in, 312-313
- risk factors in, 296-299
- trauma and, 320
- complications, 300
- gallstone, 286-289
  - diagnosis, 286-287
  - pathogenesis, 286
  - prognosis, 287
  - treatment, endoscopy, 287-289, 290
- hemorrhagic, 313-317
- and metabolic rate, 191
- necrotizing, 313-317
- Pancuronium, 968, 970-971
  - in airway management, 62
- Panthenic acid, characteristics and interactions, 670-671
- Paracentesis, large-volume, in cirrhosis, 445-446
- Patient-ventilator system check, 132-140
  - ancillary equipment, 140-141
  - assessment of need, 148
  - assessment of outcome, 148
  - complications, 147
  - components of, 133-134
  - contraindications, 147
  - described, 145-147
  - frequency of, 148-149
  - indications, 147
  - infection control issues, 149
  - limitations of, 148
  - monitoring of, 148
  - parameters to monitor during, 135-140
  - personnel for, 141
  - resources, 148
  - settings for, 147
  - timing of, 141
- Patient-controlled analgesia (PCA), with intravenous opioids, 853-854
- PEEP. *See Positive end-expiratory pressure.*
- Pentamidine, aerosolized, 91
- Pentobarbital, in ICU, 877
- Peptic ulcer, treatment, 355-357
- Peptide growth factors, for multisystem organ failure/systemic inflammatory response syndrome, 768-769
- Percussion, in chest physical therapy, 89
- Percutaneous transtracheal ventilation (PTV), in airway management, 59
- Perforation, in Crohn's disease, 524
  - ulcerative colitis and, 518
- Pericellular fluid, changes in, and metabolic regulation, 581-582
- Peritoneal lavage, for acute pancreatitis, 301-302
- Peritoneovenous shunting, in cirrhosis, 446
- Peritonitis, bacterial, spontaneous, in cirrhosis, 446-447
- Pharynx, size of, difficult airway due to, 2-3
- Phenothiazine(s), adverse effects, 1011
  - in ICU, 878
  - complications, 986-987
- Phosphate, in nutritional assessment, 628-629
- Phosphatidylinositol, for multisystem organ failure/systemic inflammatory response syndrome, 768
- Phosphorus, characteristics and interactions, 655
- Physical therapy, chest, 87-90
- Physiologic function, in nutritional assessment, 619-621
- Pipecuronium, 968, 971
- Pirenzepine, in prevention of stress-related upper gastrointestinal bleeding, 331-332
- Plasma proteins, in nutritional assessment, 609-611
- Pleur-evac, 125
- Pleural effusion, 113
  - diagnosis, 113-120
  - exudative, differential diagnosis, 113
  - radiologic signs, 113-115
  - transudative, differential diagnosis, 113
- Pleural fluid homeostasis, 112
- Pleural space, anatomy and physiology of, 111-112
- Pneumonia, nosocomial, 336-341
  - cimetidine versus sucralfate for, 340-341
  - incidence, prospective clinical studies, 337-341
  - ranitidine versus sucralfate for, 339-340
- PO<sub>2</sub>, conjunctival, 213
- Polarographic sensors, in oxygen monitoring, 200
- Portacaval shunt, for variceal hemorrhage, 395-397
- Portal hypertension, defined, 433
- Portal hypertensive gastropathy, in cirrhosis, treatment, 440-441
- Positive end-expiratory pressure (PEEP), intrinsic, and breathing, 163-164
- Positive expiratory pressure (PEP) therapy, 90
- POST, 134
- Postural drainage, in chest physical therapy, 87-89

- Potassium, total body, in nutritional assessment, 618-619
- Pre-albumin, in nutritional assessment, 612
- Pregnancy, difficult airway due to, 4
- Pressure, measurements of, 156-158
- monitoring of, 153-155
- Proctocolitis, radiation therapy and, 381
- Propofol, blood concentrations at recovery from, 883
- costs of, 884
- in ICU, 835-838, 880-884
- clinical uses, 881-883
- complications, 986
- dosage, 880
- pharmacology, 881
- precautions with, 883-884
- for sedation of agitated patients without artificial airway, 929
- studies in evaluation of, 910
- Prostaglandin(s), in inflammation, 579
- Prostaglandin E<sub>2</sub>, in prevention of stress-related upper gastrointestinal bleeding, 336
- Protein(s), in acute renal failure, 698
- in burn patients, 739
- catabolism, biocompatibility and, in acute renal failure, 694
- hemodialysis and, in acute renal failure, 693
- degradation, in acute renal failure, assessment, 690-692
- hepatic, acute-phase, functions of, 580
- during liver failure, 679-680
- metabolism of, in acute renal failure, 687-688
- in septic patients, 720-721
- for multisystem organ failure/systemic inflammatory response syndrome, 763-764
- in nutritional support, 635-650
- requirements, 635-636
- plasma, in nutritional assessment, 609-611
- in pulmonary function, 711
- requirements, in acute renal failure, 690, 692
- in septic patients, 725-726
- Proteolysis, muscle, in injured patients, 572-573
- Protozoa, diarrhea in AIDS due to, 551-552
- Pseudocyst(s), in acute pancreatitis, medical management, 303-305
- pancreatic, 318-319
- Psychosis, drugs causing, 905
- PTV. See *Percutaneous transtracheal ventilation*.
- Pulmonary disease, and metabolic rate, 191
- Pulmonary failure, acute, causes, 707
- in children, 707
- chronic, causes, 706
- malnutrition in, 706
- malnutrition and, 705-708. See also *Malnutrition, in pulmonary failure*.
- in neonates, 707
- nutritional support in, 708-713
- complications, 712-713
- goals, 708-709
- treatment regimens, 709-712
- avoidance of hypercaloric regimens, 709
- endpoints, 713
- enteral, 710
- parenteral, 710-711
- protein, 711
- Pulmonary ventilation, assurance of, 224-225
- Pulse oximetry accuracy and reliability, 208
- Pyelonephritis, in Crohn's disease, 526-527
- Pyridoxine, characteristics and interactions, 670
- QUEST procedure, 134
- Radiation therapy, lower gastrointestinal bleeding due to, 381
- Raman scattering, in oxygen monitoring, 201-202
- Ramsay Sedation Scale, 800, 804-805, 876
- Ranitidine, for nosocomial pneumonia, 339-340
- in prevention of stress-related upper gastrointestinal bleeding, 333-335
- Rapid-sequence intubation, in head trauma, 62-63
- of the unconscious or anesthetized patient, 41
- Reactive oxygen intermediates, 579
- Rectal ulcers, lower gastrointestinal bleeding due to, 383
- Rectal varices, lower gastrointestinal bleeding due to, 382
- Refeeding syndrome, 712-713
- Renal failure. See *Acute renal failure; Kidney failure*.
- Renal replacement therapy, in acute renal failure, 692-694
- Resistance, monitoring of, 154-155
- Respiratory failure, sedation for, 948-949
- Respiratory insufficiency, difficult airway due to, 6-7
- Respiratory mechanics, bedside measurements of, 159
- measurements of, 155-156



Respiratory mechanics (*Continued*)

- monitoring of, 151-167
  - in the pulmonary function laboratory, 155-156
  - properties of, 151-153
- Respiratory muscle endurance, 165-166
- Respiratory muscle strength, evaluation of, 164-165
- Respiratory procedures, issue on, 1-248
- Respiratory quotient, 173-174
- Respiratory sinus arrhythmia, in sedation assessment, 818
- Respiratory system, benzodiazepine effects on, 865-866
  - opioid effects on, 857-858
- Resting energy expenditure (REE), 572
- Retinol, characteristics and interactions, 662-664
- Retrograde intubation, in airway management, 60
  - for difficult airway, 13-14
- Reynold's pentad, 279
  - criteria, 260
- Ribavirin, aerosolized, 91
- Riboflavin, characteristics and interactions, 669
- Rocuronium, 968, 969

Saline, ultrasonic nebulized, 86-87

Scavenging, inhalational anesthetic agents and, 896-897

Sclerotherapy, endoscopic, for esophagogastric varices, 436-437
 

- in prevention of variceal hemorrhage, 405
- for variceal hemorrhage, 397-398, 402-403

Sedation. See also specific agents and *Sedative(s)*.

for cardiovascular problems, 949-950  
for CNS problems, 950-951  
in ICU, 875-886

of agitated patients without artificial airway, 913-936

airway-skilled personnel for, 916, 927

bolus versus continuous infusion of medication, 927

drugs and techniques, 926

in high-risk situations, 922-925

maintenance of sedation, 925-926

mechanical restraining devices in, 925

monitoring requirements, 923, 927  
patient evaluation, 916-917

in rapid control of combative patients, 920-921

risks and complications associated with, 931-933

treatment options, 916

complications, 791  
in control of cellular metabolism, 797-798

costs of, 1005-1019

determination of, 1010-1012

specific drug doses, 1015

strategies for reduction of, 1012-1017

drug-usage patterns, 1007-1010

goals of, 791

indications, 791-802

indiscriminate use of, 792

level of, assessment, 844

in mechanical ventilation facilitation, 792-795

monitoring of, 803-826

clinical methods for, 804-807

EEG, 807-817. See also *Electroencephalography*, in *sedation assessment*.

evoked potentials in, 819-822

neuronal networks analysis in, 818

neurophysiologic methods, 807-817

respiratory sinus arrhythmia in, 818

patients requiring, 791-802

in prevention of myocardial ischemia, 798-801

for sleep, 795-797

in kidney failure, 951-952

in liver disease, 951

for mechanically ventilated patients,

937-955. See also *Mechanical ventilation*, *sedation during*.

for recurrent agitation, 952

in respiratory failure, 948-949

*Sedative(s)*. See also specific agents and *Sedation*.

in ICU, adverse effects, 1011

combination treatment, 903-912

advantages, 905-907

disadvantages, 907-908

studies in evaluation of, 908-910

costs of, specific drug doses, 1015

ideal, 875

issues related to, 984-985

intravenous, dosing strategies for, 827-847

benzodiazepines, 829-835

fentanyl, 841, 842

lorazepam, 833-835, 836

midazolam, 829-833

morphine, 839-841

opioids, 838-841

pharmacokinetic models in, 828-829

propofol, 835-838

risks and complications associated with, 931-933

side effects, 984-985

*Sedative withdrawal syndromes*, 931

Selenium, characteristics and interactions, 656-657

- Sengstaken-Blakemore tube, for esophagogastric varices, 435-436
- Sepsis, 717-733
- abdominal, 255-272
    - algorithm for, 257
    - detection of, timelines in, 256
    - mortality due to, 255
    - primary occult, 256, 259-261
    - Ranson criteria, 260
    - secondary, dependent, 256, 261-265
      - independent, 256, 265-266
    - treatment, 266-270
  - amino acid metabolism in, 720-721
  - carbohydrate metabolism in, 718-719
  - defined, 717
  - diarrhea due to, 472-473
  - lipid metabolism in, 719-720
  - metabolic derangements in, 718-721
  - nutritional requirements in, 721-727
    - amino acids, 725-726
    - caloric, 721-722
    - carbohydrates, 722-723
    - energy, 721-722
    - implementation of, 727-730
    - lipids, 723-725
    - minerals, 726-727
    - protein, 725-726
    - vitamins, 726-727
  - overfeeding in, consequences, 722
  - protein metabolism in, 720-721
  - severe, 256
  - triglyceride metabolism in, 719-720
- Sepsis syndrome, 576
- Sequential system failure, 754
- Short bowel syndrome, infants with,
  - nutritional management in, 773-775
- Shunts, in prevention of variceal hemorrhage, 404-405
  - in prevention of variceal hemorrhage recurrence, 401-402
  - for variceal hemorrhage, 395-397
- Signal artifact, in oxygen monitoring, 207-208
- Skeletal muscle system, benzodiazepine effects on, 865
- Skinfold thickness measurement, in nutritional assessment, 607-609
- Sleep, sedation for, 795-797
- Small bowel, Crohn's disease of, 521
- Somatostatin, for esophagogastric varices, 435
  - and octreotide, for variceal hemorrhage, 394-395
- Sorbitol, diarrhea due to, 466-467
- Spectrometers, mass, in oxygen monitoring, 202-203
- Spectrometry, mass, 221-225
- Spectroscopy, near-infrared, 210
- Spine, injuries of, airway management in, 63
- Spirometry, incentive, 79-80
- Spontaneous bacterial peritonitis, 446-447
- Standard tube thoracostomy, 124
- Staple transection, esophageal, for variceal hemorrhage, 399
- Status asthmaticus, airway management in, 64
- Stomach, full, difficult airway due to, 5
- Stress, erosive gastritis due to, 359-360
  - gastritis due to, 360-361
  - mucosal disease-related, 323-345. See also *Mucosal disease, stress-related*.
  - reduction of, sedation during mechanical ventilation and, 937-940
  - upper gastrointestinal bleeding-related, 325-327
- Stridor, postextubation, causes, 31
- Subjective global assessment, in nutritional assessment, 605-607
- Substrate utilization, 187-188
- Succinylcholine, 965-966
  - in airway management, 61
  - contraindications to, 966
- Sucralfate, for nosocomial pneumonia, 339-341
  - in prevention of stress-related upper gastrointestinal bleeding, 331-332
- Suctioning, in bronchial hygiene therapy, 80-81
- Sufentanil, chemical structure of, 850
- Superior mesenteric artery embolus, management, 496-497
- Superior mesenteric artery thrombosis, acute, management, 497-498
- System impedance, 156-158
- Systemic circulation, CO<sub>2</sub> and, 229
- Systemic immune response syndrome (SIRS), 576
- Systemic inflammatory response syndrome (SIRS), 256-259
- Tactile intubation, in airway management, 60
- Taurine, for multisystem organ failure/systemic inflammatory response syndrome, 767-768
- Temperature, body, and metabolic rate, 190
- Terlipressin, for variceal hemorrhage, 394
- TEST, 134
- Theophylline, in pulmonary function, 711-712
- Thermal conductance, 588
- Thiamin, characteristics and interactions, 668-669
- Thoracentesis, 111-126
  - diagnostic, 115-120
  - therapeutic, 120

- Thoracostomy, standard tube, 124  
   trocar tube, 123  
 Thromboembolic disease, in Crohn's disease, 525-526  
 Thrombosis, mesenteric venous. See *Mesenteric venous thrombosis*.  
 Thyromental distance, difficult airway due to, 3-4  
 Tissue phase, in oxygen monitoring, 203-210  
 Tongue, size of, difficult airway due to, 2-3  
 Total parenteral nutrition, for acute pancreatitis, 301  
 Toxic megacolon, fulminant colitis and, in Crohn's disease, 524-525  
   in ulcerative colitis, 514-518  
 Toxicity, neuromuscular blocking agents and, 992-997  
 Trachea, inlet to, depiction of, 55  
 Tracheal intubation, fibroscope in, 29-51  
   nasal approach to, 39-40  
   oral approach to, 33-39  
   reasons for, 29, 31  
   of the unconscious or anesthetized patient, 40-45  
 Tracheotomy, for difficult airway, 18-19  
 Tranquilizer(s), in ICU, complications, 986-987  
 Transactions, staple, esophageal, for variceal hemorrhage, 399  
 Transferrin, in nutritional assessment, 611  
 Transhepatic intrahepatic portosystemic shunt, in cirrhosis, 446  
 Transjugular intrahepatic portosystemic shunt, for esophagogastric varices, 439-440  
   in prevention of variceal hemorrhage recurrence, 402  
   for variceal hemorrhage, 396-397  
 Transplantation, bone marrow, mucosal injury due to, 364  
   hepatocyte, for fulminant hepatic failure, 427  
   liver. See *Liver transplantation*.  
 Transtracheal jet ventilation (TTJV), for difficult airway, 16-17  
 Trauma, difficult airway due to, 4-5  
   head, rapid-sequence intubations in, 62-63  
   pancreatic, 320  
 Triglycerides, medium-chain, for multisystem organ failure/systemic inflammatory response syndrome, 769-770  
   metabolism of, in septic patients, 719-720  
 Trocar tube thoracostomy, 123  
 Tuberculosis, mycobacterium, in AIDS, 540-541  
 Tubocurarine, 967, 970  
 Tumor necrosis factor (TNF), infection and, 577-578, 581  
 Tyrosine, in nutritional support, 645  
 Ulcer(s), peptic, treatment, 355-357  
   rectal, lower gastrointestinal bleeding due to, 383  
 Ulcerative colitis, 513, 514  
   hemorrhage due to, 518-519  
   perforation due to, 518  
 Ulnar nerve, electrical stimulation of, in nutritional assessment, 621  
 Ultrasonic nebulized saline, 86-87  
 Ultrasonography, in acute cholecystitis, 260, 261  
 Urine nitrogen, measurement, in nutritional assessment, 613-614  
 Urolithiasis, in Crohn's disease, 526  
 Urosepsis, in Crohn's disease, 526  
 Uveitis, anterior, in Crohn's disease, 526  
 Varices, esophagogastric, in cirrhosis, 433-441  
   treatment, 434-440  
     beta-blockers, 435  
     endoscopic sclerotherapy, 436-437  
     endoscopic variceal ligation, 437, 438  
     Sengstaken-Blakemore tube, 435-436  
     somatostatin, 435  
     surgery, 437, 439  
     transjugular intrahepatic portosystemic shunt, 439-440  
     vasoconstrictor therapy, 434-435  
   gastric, in cirrhosis, treatment, 440  
   hemorrhagic, 391-414. See also *Hemorrhage, variceal*.  
   rectal, lower gastrointestinal bleeding due to, 382  
 Vasoconstriction, mesenteric, in acute mesenteric ischemia, 486-487  
 Vasoconstrictors, for esophagogastric varices, 434-435  
 Vasopressin, for esophagogastric varices, 434-435  
   organic nitrates with, for variceal hemorrhage, 393-394  
   for variceal hemorrhage, 393  
 Vecuronium, 968, 970  
   in airway management, 62  
 Ventilation, deadspace, 225-229  
   mechanical. See *Mechanical ventilation*.  
   metabolic measurements during, 174-181  
   monitoring of, 127-149

- percutaneous transtracheal, in airway management, 59
- pulmonary, assurance of, 224-225
- Ventilator(s), alarm features of, 130-131
- currently used, 127-131
- heat and humidity requirements of, 131
- monitoring features of, 128-129
- monitoring of, 131-141
- patient-ventilator system checks, 132-140
- support features of, 128
- Ventilatory response, variables
  - determining, 152
- Venturi masks, 74-75
- Vibration, in chest physical therapy, 89
- Vitamin(s), in acute renal failure, 698-699
- characteristics and interactions, 662-671
- fat-soluble, characteristics and interactions, 662-667
- during liver failure, 680
- for multisystem organ failure/systemic inflammatory response syndrome, 766-767
- requirements, in septic patients, 726-727
- water-soluble, characteristics and interactions, 667-671
- Vitamin A, characteristics and interactions, 662-664
- Vitamin B<sub>1</sub>, characteristics and interactions, 668-669
- Vitamin B<sub>2</sub>, characteristics and interactions, 669
- Vitamin B<sub>6</sub>, characteristics and interactions, 670
- Vitamin B<sub>12</sub>, characteristics and interactions, 671
- Vitamin C, characteristics and interactions, 667-668
- Vitamin D, characteristics and interactions, 666-667
- Vitamin E, characteristics and interactions, 665-666
- Vitamin K, characteristics and interactions, 667
- Water, for preterm neonates with multisystem organ failure/systemic inflammatory response syndrome, 759-762
  - total body, in nutritional assessment, 619
- "Watermelon stomach," treatment, 359
- Weakness, prolonged, neuromuscular blocking agents and, 991-997
- Zinc, characteristics and interactions, 660-661